1. Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure.
- Author
-
Doherty DJ, Docherty KF, and Gardner RS
- Subjects
- Humans, Heart, State Medicine, United States, Practice Guidelines as Topic, Cardiology, Heart Failure diagnosis
- Abstract
Guidelines are more accessible than ever and represent an important tool in clinical practice. The National Institute for Health and Care Excellence (NICE) has developed recommendations for heart failure diagnosis and management based not only on morbidity and mortality trial outcome data but also in-depth economic analysis, with a focus on generalisability to UK National Health Service clinical practice. There is broad consistency in structure and content between NICE guidelines and those produced by major cardiovascular organisations such as the American College of Cardiology/American Heart Association and the European Society of Cardiology. However, important differences do exist-largely attributable to publication timing-a factor that is enhanced by the rapid pace of heart failure research. This article reviews the most recent iteration of NICE chronic heart failure guidelines and compares them with major guidelines on an international scale. Variations in recommendations will be explored including implications for NICE guideline updates in the future., Competing Interests: Competing interests: DJD has no declarations. KFD’s employer, the University of Glasgow, has been remunerated by AstraZeneca for his work on the DAPA-HF and DELIVER trials; he has received speaker fees from AstraZeneca, Pharmacosomos and Radcliffe Cardiology; has served on Advisory Boards for Us2.ai and Bayer AG; has served on a Clinical Endpoint Committee for Bayer AG; and has received grant support from AstraZeneca, Roche, and Boehringer Ingelheim. RSG is the Task Force Co-ordinator for the 2021 ESC HF guidelines and the 2023 update and has received research support from Abbott and Boston Scientific and speaker/consultancy fees from Abbott, Anacardio, Astra Zeneca, Boehringer Ingelheim, Boston Scientific, Lumira Dx, Medtronic, Novartis, Occlutech, Pharmacosmos, Roche Diagnostics, and Vifor., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF